Appendix Table C54. Clinical outcomes (outcomes part B), ARB versus ARB trials

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Study** | **Stroke, Nonfatal, n/N (%)** | **Stroke, Fatal, n/N (%)** | **CHF, Any, n/N (%)** | **CHF Hospitalization (A) or Death (B), n/N (%)** | **Composite Vascular Outcome, n/N (%)\*** |
| **Interven-tion** | **Control** | **Interven-tion** | **Control** | **Interven-tion** | **Control** | **Interven-tion** | **Control** | **Interven-tion** | **Control** |
| Bakris, 200853 |  |  |  |  |  |  |  |  | TEL: 21/419 (5.0) | LOS: 37/441 (8.4) |
| Galle, 200854 |  |  |  |  |  |  | (A)7/428 (1.6) | (A)6/442 (1.4) | TEL: 31/428 (7.2) | VAL: 33/429 (7.7) |
| Burgess 200955 |  |  | CAN 64mg/d: 0/90; CAN 128mg/d: 0/89 | CAN 16mg/d: 0/90 |  |  | (B) CAN 64mg/d: 0/90; CAN 128mg/d: 0/89 | (B) CAN 16mg/d: 0/90 |  |  |
| Makino, 200737 |  |  |  |  |  |  |  |  |  |  |
| Parving, 200139IRMA-2 |  |  |  |  |  |  |  |  |  |  |

ARB = angiotensin receptor blocker; CHF = congestive heart failure; TEL = telmisartan; LOS = losartan; VAL = valsartan
\*See Composite vascular outcome definitions table